A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics

Journal of Pharmaceutical Sciences

Volumn 86, Issue 7, 1997, Pages 768-773

  Chou, J Z ^a   Place, G D ^a   Waters, D G ^a   Kirkwood, J A ^a   Bowsher, R R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LY 315902; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; IMMUNOGENICITY; INSULIN LIKE ACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RADIOIMMUNOASSAY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030790289     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9700560     Document Type: Article

References (17)

1. J.J. Holst Glucagonlike Peptide 1: A Newly Discovered Gastrointestinal Hormone Gastroenterology 107 1994 1848 1855
2. C. Ørskov Glucagon-like peptide-1, a new hormone of the entero-insular axis Diabetologia 35 1992 701 711
3. Myers, S. Personal communication.
4. R.A. Dudley P. Edwards R.P. Ekins D.J. Finney I.G.M. McKenzie G.M. Raab D. Rodbard R.P.C. Rodgers Guidelines for immunoassay data processing Clin. Chem. 31 1985 1264 1271
5. R.J. Carroll D. Ruppert Transformation and Weighting in Regression 1988 Chapman & Hall New York Chapter 3
6. M. Davidian R.J. Carroll W. Smith Variance functions and the minimum detectable concentration in assays Biometrika 75 1988 549 556
7. C. Ørskov J.J. Holst Radioimmunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) Scand. J. Clin. Lab. Invest. 47 1987 165 174
8. C. Ørskov J. Jeppesen S. Madsbad J.J. Holst Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine J. Clin. Invest. 87 1991 415 423
9. B. Kreymann G. Williams M.A. Ghatei S.R. Bloom Glucagon-like peptide-1 7–36: A physiological incretin in man Lancet 2 1987 1300 1304
10. L. Pridal S.H. Ingwersen F.S. Larsen J.J. Holst K. Adelhorst O. Kirk Comparison of sandwich enzyme-linked immunoad-sorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7–36) amide in plasma J. Pharm. Biomed. Anal. 13 1995 841 850
11. R.M. Elliott L.M. Morgan J.A. Tredger S. Deacon J. Wright V. Marks Glucagon-like peptide-1(7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J. Endocrinol. 138 1993 159 166
12. C. Ørskov L. Rabenhøj A. Wettergren H. Kofod J.J. Holst Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans Diabetes 43 1994 535 539
13. Chou, J. Z. Personal communication.
14. C.F. Deacon M.A. Nauck M. Toft-Nielen L. Pridal B. Willms J.J. Holst Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1995 1126 1131
15. C.F. Deacon A.H. Johnsen J.J. Holst Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J. Clin. Endocrinol. Metab. 80 1995 952 957
16. T.J. Kiefffer C.H.S. McIntosh R.A. Pederson Degradation of glucose-dependent insulinotrophic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase-IV Endocrinology 136 1995 3585 3596
17. J. Markussen S. Havelund P. Kurtzhals A.S. Andersen J. Halstrom E. Hasselager U.D. Larsen U. Ribel L. Schaffer K. Vad I. Jonassen Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs Diabetologia 39 1996 281 288